Problem Area Examination vs Full Body Examination: Number of Participants With Suspicious Tumors Detected After Inspection of Problem Area and Inspection of the Full Body.
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.0563 | 0.0527 | 0.0602 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.0439 | 0.0406 | 0.0473 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | 0.0124 | 0.00741 | 0.0175 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 1.28 | 1.16 | 1.42 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 1.3 | 1.17 | 1.45 | log | ClinicalTrials.gov | |
| Number needed to treat, for one more participant with the outcome on Problem Area Examination than on Full Body Examination | 80.3 | 57.1 | 135 | from the risk difference interval | ClinicalTrials.gov |
Groups 2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | Problem Area Examination | 810 | 14,381 | OG000 | ClinicalTrials.gov | |
| Group 2 | Full Body Examination | 631 | 14,381 | OG001 | ClinicalTrials.gov |
Outcome 5
| Field | Value | Source |
|---|---|---|
| Type | PRIMARY | ClinicalTrials.gov |
| Title | Number of Participants With Suspicious Tumors Detected After Inspection of Problem Area and Inspection of the Full Body. | ClinicalTrials.gov |
| Description | ClinicalTrials.gov | |
| Time frame | one year | ClinicalTrials.gov |
| Population | From a population of patients with various skin conditions, participants were considered for inclusion only if aged 18 years or more, and if suffering from focused skin complaints. Patients with diffuse skin complaints were excluded. | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | The Impact of Total Body Skin Examination on Skin Cancer Detection | ClinicalTrials.gov |
| NCT number | NCT00765193 | ClinicalTrials.gov |
| Phases | NA | ClinicalTrials.gov |
| Conditions | Melanoma, Basal Cell Carcinoma, Squamous Cell Carcinoma, Merkel Cell Carcinoma, Skin Cancer | ClinicalTrials.gov |
| Interventions | Inspection of covered areas | ClinicalTrials.gov |
| Lead sponsor | Medical University of Graz | ClinicalTrials.gov |
| Results first posted | 2010-04-15 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT00765193?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.